Digital pathology player Proscia procures $37M to expand its reach

By Author Proscia | June 15, 2022

Shortly after garnering a European green light for its digital pathology platform, the software developer Proscia has posted a $37 million venture capital round to help expand its commercial reach and seek additional product approvals.

The company previously collected $23 million in a late 2020 series B cycle. Its Concentriq Dx platform for analyzing tissue slides aims to bring together Proscia’s in-house portfolio of artificial intelligence tools, as well as plug-and-play offerings from third-party software developers, and combine them in one workflow to help clinicians check patient samples for diseases such as cancer.

Our website uses cookies. By using this site, you agree to its use of cookies.